Trinity Partners today, in tandem with the 22nd Annual International ISPOR Meeting, announced the results of a whitepaper titled, “What We Value: The Proposition Behind the Price.” The authors analyze the costliest drugs to the healthcare system approved by the FDA from 2014-2016 in order to understand the interaction between value and price. In this industry analysis, Trinity reveals the factors that appear to allow some drugs a higher price point than others and addresses key questions including: What do the most expensive drug launches in the recent past reveal about what our society values? What does the market seem to be willing to pay for?
Download the whitepaper here: http://bit.ly/2qQyKso
Trinity Partners today, in concert with the 35th Annual JP Morgan Healthcare Conference, has announced the findings of a white paper exploring the strategic decisions that successfully position a company for a maximized M&A exit. By examining the past ten years of biopharma M&A activity, Trinity has developed a framework that summaries the optimal path for private companies, taking into consideration major factors that inform valuations including financials, R&D portfolio, licensing opportunities, partnerships and more.
Download the whitepaper HERE
Trinity Partners announced today the findings of its first annual ‘Trinity Drug Index,’ a comprehensive research-based report which assessed 22 novel drugs approved by the FDA in 2013. The Index rates drug performance as measured by a retrospective look at commercial success relative to therapeutic value and R&D complexity, assigning each drug a score in those three areas as well as an overall composite score.
Top findings of this year’s Trinity Drug Index include:
- Sovaldi, which treats Hepatitis C, received the highest ranking with an overall score of 4.4 out of 5
- Most of the top performers were specialty drugs
- Drugs for primary care markets such as COPD and diabetes tend to show weaker differentiation and limited commercial performance, exacerbated by significant R&D expense
- Commercial underperformance given significant therapeutic value is rare, and could be due to a rapidly changing competitive environment
- Well-executed business strategy may boost commercial performance of drugs that are not vastly superior therapeutically
- Moving forward, it will be more critical than ever to demonstrate a product’s value vis-à-vis existing competition
If you would like to read the full whitepaper, it is available for free on the Trinity Partners website HERE.
Check out Ryan P Million’s take on drug pricing in the US oncology market and download the full white paper here, http://bit.ly/1U3iNrh